Both LMCI and AD exhibit symptoms of cognitive decline; therefore, targeted inhibition or degradation of HDAC6 as a therapeutic approach for AD could potentially have preventive effects on the occurrence of LMCI. This evidence concerns the gene HDAC6 and Alzheimer disease.